LPCN Lipocine Inc

Price (delayed)

$1.36

Market cap

$120.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.3

Enterprise value

$109.25M

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN ...

Highlights
Lipocine's equity has surged by 176% QoQ
The quick ratio has soared by 124% from the previous quarter and by 66% YoY
LPCN's net income is down by 19% YoY but it is up by 11% QoQ
The gross profit has dropped by 100% year-on-year
LPCN's revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of LPCN
Market
Shares outstanding
88.29M
Market cap
$120.08M
Enterprise value
$109.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.83
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$18.24M
EBITDA
-$18.24M
Free cash flow
-$15.99M
Per share
EPS
-$0.3
Free cash flow per share
-$0.2
Book value per share
$0.48
Revenue per share
$0
TBVPS
$0.62
Balance sheet
Total assets
$50.58M
Total liabilities
$8.19M
Debt
$4.78M
Equity
$42.39M
Working capital
$40.55M
Liquidity
Debt to equity
0.11
Current ratio
8.51
Quick ratio
8.4
Net debt/EBITDA
0.59
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-59.8%
Return on equity
-87%
Return on invested capital
-150%
Return on capital employed
-40.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LPCN stock price

How has the Lipocine stock price performed over time
Intraday
-0.73%
1 week
2.26%
1 month
1.49%
1 year
47.83%
YTD
0%
QTD
-9.93%

Financial performance

How have Lipocine's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.51M
Net income
-$18.56M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
LPCN's revenue has dropped by 100% year-on-year
LPCN's net income is down by 19% YoY but it is up by 11% QoQ
The company's operating income fell by 15% YoY but it rose by 8% QoQ

Growth

What is Lipocine's growth rate over time

Valuation

What is Lipocine stock price valuation
P/E
N/A
P/B
2.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lipocine's EPS has increased by 40% YoY and by 21% QoQ
Lipocine's equity has surged by 176% QoQ
The P/B is 43% less than the last 4 quarters average of 5.0 and 21% less than the 5-year quarterly average of 3.6
LPCN's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Lipocine business performance
The ROIC has soared by 68% from the previous quarter and by 14% YoY
Lipocine's ROE has soared by 58% YoY and by 49% from the previous quarter
LPCN's ROA is up by 33% since the previous quarter and by 25% year-on-year

Dividends

What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LPCN.

Financial health

How did Lipocine financials performed over time
Lipocine's total assets has surged by 141% YoY and by 99% QoQ
The quick ratio has soared by 124% from the previous quarter and by 66% YoY
LPCN's debt is 89% smaller than its equity
Lipocine's equity has surged by 176% QoQ
The debt to equity has dropped by 89% year-on-year and by 69% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.